| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 12/05/2002 | US20020183339 Medicament for prevention and treatment of dermatitis having chymase inhibitor as effective ingredient |
| 12/05/2002 | US20020183338 Preventive or therapeutic drugs for fibrosis containing chymase inhibitors as the active ingredient |
| 12/05/2002 | US20020183335 2, 4-disubstituted pyrimidine-5-carboxamide derivatives as KCNQ potassium channel modulators |
| 12/05/2002 | US20020183334 For therapy of sleepiness, promotion of wakefulness, treatment of Parkinson's disease, cerebral ischemia, stroke, sleep apneas, eating disorders, stimulation of appetite and weight gain, treatment of attention deficit hyperactivity disorder |
| 12/05/2002 | US20020183333 Compositions and methods for chemotherapy having reduced nephrotoxicity |
| 12/05/2002 | US20020183332 Substituting for the benzodiazepine in a patient in need thereof, a benzodiazepine withdrawal symptom alleviating effective dose of cyamemazine, or a pharmaceutically acceptable salt thereof |
| 12/05/2002 | US20020183329 Antidepressant azaheterocyclylmethyl derivatives of 2,3-dihydro-1,4-dioxino[2,3-f]quinoxaline |
| 12/05/2002 | US20020183328 Method of using (2-imidazolin-2-ylamino) quinoxalines in treating ocular neural injury |
| 12/05/2002 | US20020183327 For use as analgesics |
| 12/05/2002 | US20020183326 1,2,4-triazolo[4,3-B]pyrido[3,2-D]pyridazine derivatives and pharmaceutical compositions containing them |
| 12/05/2002 | US20020183325 Phthalazinone derivatives |
| 12/05/2002 | US20020183324 Monocyclic or bicyclic carbocycles and heterocycles as factor Xa inhibitors |
| 12/05/2002 | US20020183323 For therpay of inflammatory bowel disease, cerebral ischemia and arthritis, adult respiratory distress syndrome (ARDS) and myocarditis, as adjuvants to short term immunosuppression in transplant therapy |
| 12/05/2002 | US20020183321 Carbocyclic and heterocyclic substituted semicarbazones and thiosemicarbazones and the use thereof |
| 12/05/2002 | US20020183320 For use as analgesics |
| 12/05/2002 | US20020183319 For therapy of blood vessel proliferative disorders; fibrotic disorders; mesangial cell proliferative disorders; metabolic disorders; allergies; asthma; thrombosis; nervous system diseases; and cancer |
| 12/05/2002 | US20020183318 Novel derivatives of flavones, xanthones and coumarins |
| 12/05/2002 | US20020183317 Administering thiazole compound for therapy of fibrotic diseases |
| 12/05/2002 | US20020183316 Amidoalkyl-piperidine and amidoalkyl-piperazine derivatives useful for the treatment of nervous system disorders |
| 12/05/2002 | US20020183314 For therapy of acne, male- pattern baldness, sexual dysfunction, impotence, wasting diseases, hirsutism, hypogonadism, prostatic hyperplasia, osteoporosis, cancer cachexia, and hormone-dependent cancers |
| 12/05/2002 | US20020183313 Cholecystokinin-A and B (CCK-A/B) antagonists and useful in therapy and prophylaxis of disorders of appetite regulatory systems (e.g., anorexia) disorders associated with intestinal smooth muscle hyperactivity (e.g., irritable bowel syndrome) |
| 12/05/2002 | US20020183312 Combination of cyamemazine and an atypical neuroleptic |
| 12/05/2002 | US20020183311 Novel hydroxy cyclohexenyl phenyl carboxamides tocolytic oxytocin receptor antagonists |
| 12/05/2002 | US20020183308 Benazepril Hydrochloride tablet formulations |
| 12/05/2002 | US20020183306 Combination treatment for sleep disorders including sleep apnea |
| 12/05/2002 | US20020183305 For therapy of hyperlipidemic conditions such as are associated with atherosclerosis, hypercholesterolemia and other vascular conditions in mammals |
| 12/05/2002 | US20020183304 For prophylaxis or reducing neuronal damage in patients suffering from or susceptible to disease states characterized by loss of neuronal cells or loss of neuronal cell function |
| 12/05/2002 | US20020183303 Activity as selective serotonin re- uptake inhibitors (SSRIs); for therapy and prophylaxis of depression, attention deficit hyperactivity disorder, obsessive- compulsive disorder, post-traumatic stress disorder, sexual dysfunction |
| 12/05/2002 | US20020183300 Zinc ionophores as anti-stress agents |
| 12/05/2002 | US20020183299 Administering at least one primary agent being an estrogen or estrogen receptor active agent at a therapeutically effective dosage in an effective dosage form at a selected interval to ameliorate the symptoms of the autoimmune disease |
| 12/05/2002 | US20020183298 Pharmaceutical and food compositions containing" wood alcohols" or" wood sterols" useful for lowering serum cholesterol |
| 12/05/2002 | US20020183296 Applying a hydroalcoholic gel containing testosterone to skin of the male subject in an amount effective to treat the hypogonadism |
| 12/05/2002 | US20020183294 Therapy and prophylaxis of cognitive dysfunction in a human or non-human animal by administering sapogenin derivatives wherein the E and/or F ring of the fused ring system has been cleaved |
| 12/05/2002 | US20020183293 Administering durg comprising formoterol, or a derivative thereof and asteroidal anti-inflammatory agent, or a derivative in a pharmacologically suitable fluid, wherein the drug formulation is stable during long term storage |
| 12/05/2002 | US20020183292 For therapy of respiratory tract diseases |
| 12/05/2002 | US20020183291 Use of an aromatase inhibitor selected from exemestane, anastrozole, letrozole and fadrozole in the preparation of a medicament for use in treating gynecomastia in a patient undergoing treatment with antiandrogen |
| 12/05/2002 | US20020183290 Administering alpha 1- adrenergic receptor ligand for therapy of lower-urinary-tract symptoms (LUTS) in a mammal |
| 12/05/2002 | US20020183289 1alpha-hydroxy-2-methylene-19-nor-homopregnacalciferol and its uses |
| 12/05/2002 | US20020183288 Administering to a subject suffering from hyperparathyroidism an amount of active vitamin D formula sufficient to lower or maintain lowered blood parathyroid hormone (PTH) levels |
| 12/05/2002 | US20020183287 Method of producing a concentrate comprising a sulfonamide in solution, a 2,4-diaminopyrimidine in stable suspension within said solution |
| 12/05/2002 | US20020183286 Taurine compounds |
| 12/05/2002 | US20020183284 For dermatitis caused by exposure to the toxin urushiol; provides complete relief from the signs and symptoms associated with the dermatitis in limited solutions and be effective at any point during the dermatitis cycle |
| 12/05/2002 | US20020183283 Meiosis regulating compounds |
| 12/05/2002 | US20020183282 For skin, muscle, ocular or gastric mucosal healing |
| 12/05/2002 | US20020183281 For therapy and prophylaxis of disorders that are ameliorated by the inhibition of neuronal monoamine uptake in mammals; disorders including erectile dysfunction, affective disorders, obesity, cerebral function disorders, pain |
| 12/05/2002 | US20020183280 For controlled administration of pharmaceutically active agents to patients, wherein formulation is administered as liquids which thicken to form gels upon instillation into the eye |
| 12/05/2002 | US20020183279 For therapy and prophylaxis of infections and inflammations associated with intraocular surgery and intra-articular injection |
| 12/05/2002 | US20020183278 For therapy and prophylaxis of painful ulcerative and inflammatory conditions of moist surfaces such as mouth, oropharynx, oesophagus, vagina and rectum (e.g., mucositis, stomatitis, aphthous ulcerations, and Behcet' syndrome) |
| 12/05/2002 | US20020183277 Combination of vitamin D analogue and pyrimidine nucleoside analogue |
| 12/05/2002 | US20020183276 Administering alkaline phosphatase (TNAP) inhibitor to the tissue or patient effective to inhibit TNAP expression or activity for decreasing matrix mineralization in a tissue |
| 12/05/2002 | US20020183271 Administering to the patient a human MDA-7 polypeptide or a nucleic acid expressing the human MDA-7 polypeptide in eukaryotic cells, whereby the MDA-7 polypeptide inhibits angiogenesis in the patient |
| 12/05/2002 | US20020183269 Novel compounds |
| 12/05/2002 | US20020183267 For use as antibiotics; for therapy of Staphylococcus aureas infection |
| 12/05/2002 | US20020183266 Combination comprising combretastatin and anticancer agents |
| 12/05/2002 | US20020183265 Manufacture and use of an antibiotic/antibiotics preparation |
| 12/05/2002 | US20020183264 Use of harpagid-related compounds for prevention and treatment of osteoporosis, arthritis and ruptured disc and pharmaceutical composition containing the same |
| 12/05/2002 | US20020183263 Nutritional preparation comprising ribose and medical use thereof |
| 12/05/2002 | US20020183261 Oral administration of these can stimulate proliferation of osteoblast, inhibit bone resorption and strengthen bone; can be useful for improvement of osteoporosis, bone fracture, bone pain, etc |
| 12/05/2002 | US20020183259 Terminally-branched polymeric linkers and polymeric conjugates containing the same |
| 12/05/2002 | US20020183250 For use in therapy of sleep disorders |
| 12/05/2002 | US20020183246 Use of thiamphenicol for the preparation of a pharmaceutical useful for the treatment of vancomycin- intermediates and multiresistant staphylococci infections |
| 12/05/2002 | US20020183245 For therapy of Porphyromonas (Bacteroides) gingivalis; periodontal disorder |
| 12/05/2002 | US20020183244 Coating endoluminal surface of a tissue by coating with water soluble proteinaceous material and with di- or polyaldehyde; allowing formulation to cure |
| 12/05/2002 | US20020183241 Methods for treating vertigo and motion sickness using descarboethoxyloratadine |
| 12/05/2002 | US20020183240 Antineoplastic combinations |
| 12/05/2002 | US20020183239 Administering effective amount of a combination comprising an mTOR inhibitor and an antimetabolite antineoplastic agent for therapy of neoplasm in mammal |
| 12/05/2002 | US20020183237 Methods of performing vagal-induced asystole |
| 12/05/2002 | US20020183205 Use of alpha2-adrenergic receptor agonists and adrenergic inhibitors in reducing defoliation |
| 12/05/2002 | US20020182725 New antigen presenting cells, a process for preparing the same and their use as cellular vaccines |
| 12/05/2002 | US20020182659 Method to determine TGF-beta |
| 12/05/2002 | US20020182655 Method for identifying ligands for G protein-coupled receptors |
| 12/05/2002 | US20020182650 Inhibitors of binding between proteins and macromolecular ligands |
| 12/05/2002 | US20020182643 Detecting preferential ligands in cell; obtain cell, incubate with reporter molecules, detect reporter in cell |
| 12/05/2002 | US20020182612 Diagnosing inflammatory defects in humans; obtain nucleotide sequence sample, incubate with probe associated with preferential allele, detect hybridization, hybridization indicates sensitivty to inflammatory defect |
| 12/05/2002 | US20020182585 Therapeutic treatment for vascular defects |
| 12/05/2002 | US20020182581 Treating blood or blood products with compounds which have a mustard, aziridinium or aziridine group and a nucleic acid binding group |
| 12/05/2002 | US20020182277 Bioactivity of methyl palmitate obtained from a mangroove plant Salvadora persica L |
| 12/05/2002 | US20020182273 Composition and method useful for treating colic |
| 12/05/2002 | US20020182272 Methods of treatment of HIV-associated conditions |
| 12/05/2002 | US20020182268 Plant extracts, especially for breast cancer |
| 12/05/2002 | US20020182267 Compositions to control oral microbial oxidation-reduction (Eh) levels |
| 12/05/2002 | US20020182266 Vitamin C, vitamin E, beta-carotene, zinc and copper, preferably in tablet form |
| 12/05/2002 | US20020182264 Mixture of 2 inorganic and 1 organic acids has a pH of less than 1; noncaustic to human tissue; safe for human ingestion; cleansers, pharmaceuticals, food preservatives and disinfectants; medical & industrial applications |
| 12/05/2002 | US20020182256 Novel oral dosage form for carvedilol |
| 12/05/2002 | US20020182255 Especially a sustained release composition for the treatment of ocular and periocular infections. |
| 12/05/2002 | US20020182253 Sustained-release microgranules containing diltiazem as active principle |
| 12/05/2002 | US20020182251 Antibiotic(s) preparation with retarding active ingredient release |
| 12/05/2002 | US20020182249 Preparation of stable formulations of lipid-nucleic acid complexes for efficient in vivo delivery |
| 12/05/2002 | US20020182247 Patches containing buprenorphine hydrochloride |
| 12/05/2002 | US20020182237 Skin care compositions containing a sugar amine |
| 12/05/2002 | US20020182227 Treatment of virus using chelator and antiviral agent |
| 12/05/2002 | US20020182217 Time release chelators |
| 12/05/2002 | US20020182215 Especially the amino acid sequence Ile-Phe-Ala-Gly-Asp-Lys-Phe-Trp-Arg, preferably flanked by cysteine residues at the amino and carboxy termini. |
| 12/05/2002 | US20020182214 Tumor associated internalizing antigens and methods for targeting therapeutic agents |
| 12/05/2002 | US20020182210 Treatment of central nervous system diseases by antibodies against glatiramer acetate |
| 12/05/2002 | US20020182207 Contacting said target molecule with a catalyst capable of chemically modifying said target molecule; catalyzing the attachment of the label to the target substance |
| 12/05/2002 | US20020182204 Combination of a taxane and a cyclin-dependent kinase |
| 12/05/2002 | US20020182199 Skin Care agents containing combinations of active agents consisting of vitamin a derivatives and ubi-or plastoquinones |
| 12/05/2002 | US20020182196 Composition and method for normalizing impaired or deteriorating neurological function |
| 12/05/2002 | US20020182187 Method of decreasing radiation or radio-mimetic chemotherapy for hematopoietic pluripotent cell engraftment |